MetLife Investment Advisors LLC purchased a new position in FibroGen (NASDAQ:FGEN) during the 4th quarter, Holdings Channel reports. The firm purchased 31,200 shares of the biopharmaceutical company’s stock, valued at approximately $1,479,000.
A number of other institutional investors have also modified their holdings of FGEN. Bank of Montreal Can raised its position in FibroGen by 2,097.2% in the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. raised its position in FibroGen by 95.0% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 1,700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in FibroGen by 41.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 1,147 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 2,336 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in FibroGen in the fourth quarter worth about $255,000. Hedge funds and other institutional investors own 61.39% of the company’s stock.
NASDAQ FGEN opened at $44.90 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. The stock has a market cap of $3,720.01, a price-to-earnings ratio of -25.95 and a beta of 1.89. FibroGen has a 1 year low of $24.25 and a 1 year high of $63.00.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. The firm had revenue of $42.51 million for the quarter, compared to the consensus estimate of $45.37 million. FibroGen had a negative return on equity of 32.08% and a negative net margin of 100.43%. sell-side analysts expect that FibroGen will post -1.35 earnings per share for the current year.
In other FibroGen news, VP Pat Cotroneo sold 49,500 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $55.96, for a total transaction of $2,770,020.00. Following the sale, the vice president now owns 207,392 shares in the company, valued at approximately $11,605,656.32. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $47.64, for a total value of $900,396.00. Following the transaction, the chief executive officer now directly owns 2,981,447 shares in the company, valued at approximately $142,036,135.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 427,799 shares of company stock worth $22,937,028. Corporate insiders own 13.60% of the company’s stock.
FGEN has been the topic of several research reports. TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. Leerink Swann restated an “outperform” rating and set a $88.00 price objective (up previously from $80.00) on shares of FibroGen in a report on Wednesday, February 28th. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. ValuEngine upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Mizuho restated a “hold” rating and set a $61.00 price objective on shares of FibroGen in a report on Thursday, March 29th. Two research analysts have rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. FibroGen has a consensus rating of “Hold” and an average target price of $66.67.
ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/metlife-investment-advisors-llc-invests-1-48-million-in-fibrogen-fgen-stock.html.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.